Results 201 to 210 of about 133,265 (260)

Investigating rituximab-induced infusion-related reactions in patients with non-Hodgkin lymphoma, with a focus on follicular lymphoma: a retrospective observational study. [PDF]

J Pharm Health Care Sci
Hirobe S, Fukada K, Miyamoto M, Inukai M, Fujimoto R, Maeda S, Maeda M, Fujio Y.   +7 more
europepmc   +1 more source

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma. [PDF]

Clin Transl Sci
Tachibana M, Horwitz S, Jacobsen E, Foss F, Allen P, Porcu P, Feldman T, Ruan J, Brammer JE, Wang J, Inaba S, Iko Y, Nakajima K, Kakurai Y, Kitami N, Chen Y, Lau Y.   +16 more
europepmc   +1 more source

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Blood
Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, Relf J, Briner S, Varol A, Appelt B, Domocos I, Nicolini V, Bez M, Bommer E, Jenni S, Schoenle A, Le Clech M, Colombetti S, Klein C, Umaña P, Lundberg P, Korfi K, Bottos A, Bacac M.   +23 more
europepmc   +1 more source

Prospective pooled analyses of ambient ultraviolet radiation levels and risk of non-Hodgkin lymphoma and multiple myeloma. [PDF]

Am J Epidemiol
Wang SS, Bertrand KA, Deubler EL, Chao CR, Birmann BM, Teras LR, Rosner BA, McCullough M, Shu YH, Wang K, Zhong C, Cauble EL, Patel AV, Lacey JV, Cockburn M.   +14 more
europepmc   +1 more source

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

HemaSphere, Volume 10, Issue 4, April 2026.
Allison M. Bock, Peirong Hao, Yizhe Xu, Efrat Luttwak, Swetha Kambhampati Thiruvengadam, Kanithra Sekaran, Dahlia Sano, John Vaughn, John Sharp, Ajay Major, Vrutti Patel, Gordon Smilnak, Nicole Araujo, Ritwick Mynam, Daniel Reef, Marisa Palmeri, Drew Gerber, Anuja Abhyankar, Grace Baek, Ayo Falade, Madiha Iqbal, Boyu Hu, Praveen Ramakrishnan Geethakumari, Urshila Durani, Mengyang Di, Alex Niu, Hua‐Jay J. Cherng, Joanna M. Rhodes, Natalie Grover, Priyanka Pophali, Tatyana Feldman, Krithika Shanmugasundaram, Jakub Svoboda, Timothy Voorhees, Catherine Diefenbach, Yasmin Karimi, Reem Karmali, Alex F. Herrera, Pallawi Torka, Narendranath Epperla   +39 more
wiley   +1 more source

Correlates and Detection of Digital Health Literacy in Patients With Colorectal Carcinoma or Non-Hodgkin Lymphoma: Cross-Sectional Study.

JMIR Cancer
Gunning TS, Khoudary A, Billini O, Ip A, Sorgen L, Marshall J, Weinberg BA, Potosky AL, Schwartz MD, Conley CC, Derry-Vick HM.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-Hodgkin's lymphoma

European Journal of Cancer, 1998
To review the etiology, epidemiology, classification, diagnosis, staging, prognosis, treatment, and nursing implications of non-Hodgkin's lymphoma.Research studies, review articles, and book chapters pertaining to non-Hodgkin's lymphoma.Non-Hodgkins's lymphomas are a heterogeneous group of lympho-proliferative disorders, increasing in frequency, for ...
B A, Bilodeau, K L, Fessele
openaire   +4 more sources

Non-Hodgkin Lymphoma

The Lancet, 2017
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and be seen by primary care physicians and physicians from most specialties. They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar.
Zeppa P., Cozzolino I.
openaire   +4 more sources

Non-Hodgkin lymphoma

The Lancet, 2012
Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin lymphoma. Non-Hodgkin lymphomas have a wide range of histological appearances and clinical features at presentation, which can make diagnosis difficult.
Kate R, Shankland, James O, Armitage, Barry W, Hancock   +2 more
openaire   +2 more sources